CRISPR Therapeutics

CRISPR Therapeutics AG is a Swiss-American biotechnology company headquartered in Zug. In fiscal year 2019, the company had revenues of $289.59 million, with net income of $66.86 million. In the same year, the number of employees stood at 304.[3] As of early 2021, the company had a market capitalization of over $13 billion.[4] CRISPR Therapeutics' investors include German chemical company Bayer.

CRISPR Therapeutics
TypePublic
NASDAQ: CRSP
ISINCH0334081137
IndustryBiotechnology
Founded2013
FounderEmmanuelle Charpentier, Shaun Foy and Rodger Novak,Jennifer Doudna [1]
HeadquartersZug, Switzerland,


Cambridge, Massachusetts[2]
Key people
Samarth Kulkarni
(CEO)
RevenueUS$289.59 million (2019)
US$46.74 million (2019)
US$46.74 million (2019)
Total assetsUS$1.067 billion (2019)
Number of employees
304 (2019)
Websitewww.crisprtx.com

History

CRISPR Therapeutics was founded in 2013. One of the co-founders is Emmanuelle Charpentier, who later won the Nobel Prize in Chemistry in 2020. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and exchanged, which can for example prevent diseases. The company CRISPR Therapeutics is to apply this new technology commercially and advance research.[5]

In 2016, the company went public on NASDAQ.[6] In August 2016 the company started to operate Casebia Therapeutics, as a joint venture with Bayer. In 2019, Casebia Therapeutics came directly under the control of CRISPR Therapeutics.[7]

Products

The company has several drugs in development. These include the drug CTX001 for the treatment of the rare blood disorders Beta thalassemia and sickle cell disease, which is being developed jointly with Vertex Pharmaceuticals.[5] In May 2020, CTX001 received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia.[8]

References
  1. http://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-congratulates-scientific-founder-dr
  2. Cambridge, Massachusetts
  3. "CRISPR THERAPEUTICS Bilanz GuV | Kennzahlen | Umsatz | Gewinn". finanzen.net (in German). Retrieved 2021-01-08.
  4. "CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History - Yahoo Finance". finance.yahoo.com. Retrieved 2021-01-08.
  5. "CRISPR Therapeutics: Ist diese Aktie nobelpreiswürdig?". GodmodeTrader (in German). Retrieved 2021-01-08.
  6. "Börsengang von CRISPR Therapeutics an der NASDAQ". VISCHER (in German). Retrieved 2021-01-08.
  7. "Bayer backs off running Casebia JV as CRISPR Tx takes over management". FierceBiotech. Retrieved 2021-01-08.
  8. CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies, PM Vertex May 11, 2020; retrieved May 11, 2020
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.